Viking Therapeutics: High Risk, High Reward

Viking Therapeutics, VKTX, presents a high-risk, high-reward opportunity amid market volatility. Despite a 15% drop this year, Wall Streets average price target suggests a potential 207% jump in the next twelve months. The companys flagship drug, VK2735, is in phase three trials for obesity, a prevalent issue with limited treatment options. Early phase two results showed promising weight loss, and additional trials are underway. While success could lead to significant gains, failure may result in a stock drop. Investors should be prepared for market swings. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9fa1201f5a3fec5c